CAMP4 Buys Global Rights to OPKO Health’s RNA-based Therapeutics

CAMP4 Buys Global Rights to OPKO Health’s RNA-based Therapeutics

301583

CAMP4 Buys Global Rights to OPKO Health’s RNA-based Therapeutics

CAMP4 Therapeutics has entered an exclusive worldwide licensing agreement to develop, manufacture, and commercialize OPKO Health’s RNA-based technology as potential disease-modifying treatments for Dravet syndrome. As part of the deal, CAMP4 has prioritized OPKO’s lead candidate for Dravet to enter clinical development. “We are delighted to enter into this licensing agreement to accelerate the development and commercialization of potential disease-modifying therapeutics,” Phillip Frost, MD, chairman and CEO of OPKO, said in a press release. “With a clear…

You must be logged in to read/download the full post.